The European Union failed in legal attempts to force Astrazeneca to speed up the transfer of 300 million doses of Vaccine Covid-19.

British - Sweden Astrazeneca pharmaceutical company on June 18 said the European Union (EU) lost in the first lawsuit of the block aimed at this vaccine producer, in an effort to promote the supply of Vaccine Covid-19.

The dispute with Astrazeneca pushes the EU to fall into the crisis at the beginning of the year, when the countries won the vaccine under pressure to accelerate the vaccination progress.

Astrazeneca's Vaccine Covid-19 at the vaccination center in Nuremberg, southern Germany, on March 18.

AstraZeneca has committed its best effort to provide 300 million doses for 27 EU countries at the end of June, but the production speed slowly forced them to adjust this number to 100 million.

This has delayed the EU vaccination campaign, because the original alliance bet on Astrazeneca can provide the largest number of vaccines.

Judge yesterday ruled that Astrazeneca only had to provide 80.2 million doses to the EU before the deadline of September 27.

The judge announced that if it was not responded on time, Astrazeneca will face a 10-euro (US $ 11.8) penalty for each missing dose, less than the fine of 10 euros per dose for a slow day of the transfer that the EU desires.

Astrazeneca continues to try to provide 300 million doses to the EU and the court decided to open a new hearing in September to re-evaluate the contract progress.

EU data showed that Astrazeneca moved nearly 70 million doses, of which more than half was handed over as soon as the EU sued.

A EU lawyer said this ruling was evidence for attempting to force Astrazeneca to provide Vaccine Covid-19 from a factory in the UK if needed to meet commitments with the EU.

The company ever expressed instantly providing vaccines from Oxford Biomedia Factory to the EU because he had to transfer to him first.

Astrazeneca said that the Court found that the EU did not have exclusive rights or priorities compared to other parties.

The ruling also acknowledged that Astrazeneca was unprecedented and this had a significant impact on the delivery schedule, the company announced.

Meanwhile, Chairman of the European Commission Ursula von der Leyen said the court ruling also supported the views of the block that the company did not comply with the commitment.